Document is current
Any future updates will be listed below
-
Authors
Godfrey, Elizabeth L.
Schultz, Kurt S.
Bansal, Varun V.
Su, David G.
Butensky, Samuel D.
Brown, Leanne M.
Godley, Frederick A.
Mahoney, Forest
Wilkins, Sarah
Izquierdo, Francisco
Gunderson, Craig G.
Turaga, Kiran K.
-
Funding
Funding for this research was provided by:
National Institutes of Health Immuno-Oncology Advanced Training Program (David G. Su [T32 CA233414])
National Institutes of Health National Cancer Institute Loan Repayment Program (Elizabeth L. Godfrey [1L30CA294369-01])
Irving Harris Foundation (Varun V. Bansal was supported by this foundation)
- License Information
-
More Information
Article History
Received: 28 January 2026
Accepted: 20 April 2026
First Online: 2 May 2026
Disclosure
: During all or part of the described study, Elizabeth L. Godfrey was supported by the NIH NCI loan repayment program (1L30CA294369-01). Varun V. Bansal was supported by a grant from the Irving Harris Foundation. David G. Su was supported by the NIH Immuno-Oncology Yale Cancer Center Advanced Training Program (T32 CA233414). Kiran Turaga reports serving on the Astra Zeneca advisory board. The remaining authors have no conflicts of interest.
Free to read: This content has been made available to all.
